<DOC>
	<DOCNO>NCT00632424</DOCNO>
	<brief_summary>This Phase 1 study oral ixabepilone give every 6 hour 3 dos Day 1 , every 21 day , dose-finding study design determine maximum tolerate dose ( MTD ) safety dose schedule participant advance cancer</brief_summary>
	<brief_title>Phase 1 Trial Oral Ixabepilone</brief_title>
	<detailed_description />
	<mesh_term>Epothilones</mesh_term>
	<criteria>Males female , 18 old Histologically cytologically confirm diagnosis solid tumor malignancy Measurable nonmeasurable disease define Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion Karnofsky Performance Status ( KPS ) 70100 Recovered toxicity result previous therapy More 3 prior cytotoxic regimen metastatic set Current recent gastrointestinal ( GI ) disease would impact absorption study drug Inability swallow whole capsule Inadequate hepatic renal function Function exposure epothilone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>